T W Stief
Overview
Explore the profile of T W Stief including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stief T
Int J Lab Hematol
. 2008 Jul;
30(4):269-77.
PMID: 18665823
Thrombin generation depends on the surface of the blood vessel or container. With a new ultra-sensitive and -specific thrombin assay the surface-dependent thrombin generation was quantified. Citrated blood or plasma...
2.
Stief T
Clin Appl Thromb Hemost
. 2006 Sep;
12(3):324-9.
PMID: 16959686
Thrombin is the key enzyme of coagulation. Its activity can be determined via fibrinogen Ø fibrin conversion or via cleavage of a chromogenic substrate. The latter method is easier than...
3.
Stief T, Richter A, Bunder R, Maisch B, Renz H
Clin Appl Thromb Hemost
. 2006 May;
12(2):213-8.
PMID: 16708124
There are no reliable data on plasmin or plasminogen activator (PA) activities in blood of patients receiving fibrinolytic treatment. This is due to continuing in vitro action of PA after...
4.
Stief T
Clin Appl Thromb Hemost
. 2006 May;
12(2):137-61.
PMID: 16708116
Pathologic disseminated intravascular coagulation (PDIC) is a serious complication in sepsis. In an in-vitro system consisting of incubation of fresh citrated blood with lipopolysaccharides (LPS) or glucans and subsequent plasma...
5.
Stief T, Richter A, Bunder R, Maisch B, Renz H
Clin Appl Thromb Hemost
. 2005 Jul;
11(3):311-23.
PMID: 16015417
Reliable data on plasminogen activator (PA) activities in blood of patients receiving fibrinolytic treatment are lacking. This is due to the continuing in vitro action of PA after blood withdrawal....
6.
Stief T, Richter A, Bunder R, Maisch B, Renz H
Clin Appl Thromb Hemost
. 2005 Jul;
11(3):303-9.
PMID: 16015416
Reliable data on plasmin activities in blood of patients during fibrinolytic treatment are lacking. This is due to continuing plasminogen activation by plasminogen activators after blood withdrawal. The purpose of...
7.
8.
Stief T, Bunder R, Richter A, Maisch B, Renz H, Fareed J
Clin Appl Thromb Hemost
. 2003 Sep;
9(3):211-20.
PMID: 14507109
One type of therapy for thromboembolism is plasmatic thrombolysis. Several plasminogen activators (PA) are clinically available, including urokinase (u-PA), tissue plasminogen activator (t-PA), streptokinase (SK), plasminogen-streptokinase-activator-complex (PSAC), or mutants of...
9.
Stief T, Feek U, Ramaswamy A, Kretschmer V, Renz H, Fareed J
Thromb Res
. 2001 Dec;
104(5):361-70.
PMID: 11738079
Introduction: Important mediators of activated polymorphonuclear leukocytes (PMN) are the oxidants HOCl and chloramine, which generate the nonradical photon-emitting oxidant singlet oxygen (1O(2)). Since 1O(2) inhibits platelet aggregation, we became...
10.
Stief T, Weippert M, Kretschmer V, Renz H
Thromb Res
. 2001 Dec;
104(4):265-74.
PMID: 11728528
Background: The diagnosis and the therapy of in vivo hemostasis activation is of great clinical importance. Artefactual changes of the hemostasis (i.e., coagulation or fibrinolysis) in vitro have to be...